Spike Protein News and Research

RSS

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Compound may block COVID-19 virus from entering lung cells, study reports

Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that Elovanoids, bioactive chemical messengers made from omega-3 very-long-chain polyunsaturated fatty acids discovered by the Bazan lab in 2017, may block the virus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung.

10 Jun 2021

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.

10 Jun 2021

SARS-CoV-2 enzyme inhibitors among drugs screened for repurposing

A new bioRxiv* preprint describes the identification of some promising pharmaceutical compounds that could be developed as antiviral drugs against COVID-19.

9 Jun 2021

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Researchers in the United States and Canada have identified DNA on/off “switches” within the angiotensin-converting enzyme 2 (ACE2) gene that may control the expression of this host cell receptor before, during and after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

9 Jun 2021

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

A new bioRxiv preprint attempts to make some sense of why certain people experience more severe forms of COVID-19 as compared to others by pointing to the increase in virus binding that occurs in the presence of smoking or vaping.

9 Jun 2021

Researchers in Canada conduct a comparative study of household secondary attack rates connected with SARS-CoV-2 variants of concern

Scientists are considering a third surge in COVID-19 incidence owing to the emergence of highly transmissible SARS-CoV-2 variants of concern (VOC). SARS-CoV-2 is the causal agent of the current COVID-19 pandemic. Some of these VOCs have been reported to have a rate of transmission much higher than the infectivity of the ancestral strain that had emerged in Wuhan, China, in 2019.

9 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

Mix and match COVID-19 vaccines safe and effective: German study

A new preprint study posted to the medRxiv* server shows an AstraZeneca’s ChAdOx1-nCov-19 and Pfizer/BioNTech BNT162b2 COVID-19 vaccine combination is immunologically superior to two AstraZeneca ChAdOx1-nCov-19 doses.

9 Jun 2021

Senolytics reduce inflammation, illness, and mortality from COVID in older mice

Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body.

9 Jun 2021

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

In a paper recently uploaded to the preprint server medRxiv* by Nakajima et al. (June 4th, 2021), the antibody responses of over 2,000 Japanese healthcare workers were tracked over a period of several months, with particular regard to serum Immunoglobulin G (IgG) against the SARS-CoV-2 spike protein.

8 Jun 2021

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

New atomic-level model helps explain how SARS-CoV-2 causes extensive lung damage

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have published the first detailed atomic-level model of the SARS-CoV-2 "envelope" protein bound to a human protein essential for maintaining the lining of the lungs.

8 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

A team of researchers at MIT has developed a molecular assay to detect sub-picomolar levels of the SARS-CoV-2’s spike protein receptor-binding domain (S-RBD) using computationally validated peptide beacons in a single-step detection through the production of a fluorescence signal.

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

Spike Protein News and Research

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Compound may block COVID-19 virus from entering lung cells, study reports

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

SARS-CoV-2 enzyme inhibitors among drugs screened for repurposing

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

Researchers in Canada conduct a comparative study of household secondary attack rates connected with SARS-CoV-2 variants of concern

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Mix and match COVID-19 vaccines safe and effective: German study

Senolytics reduce inflammation, illness, and mortality from COVID in older mice

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

New atomic-level model helps explain how SARS-CoV-2 causes extensive lung damage

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers identify a novel host-directed therapeutic approach to COVID-19

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News